| Title |
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
|
|---|---|
| Published in |
Cancer Immunology Research, May 2017
|
| DOI | 10.1158/2326-6066.cir-16-0325 |
| Pubmed ID | |
| Authors |
Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Katy K. Tsai, Kimberly L. Loo, Matthew A. Gubens, Michael Rosenblum, Christina L. Harview, Janis M. Taube, Nathan Handley, Neharika Khurana, Adi Nosrati, Matthew F. Krummel, Andrew Tucker, Eduardo V. Sosa, Phillip J. Sanchez, Nooriel Banayan, Juan C. Osorio, Dan L. Nguyen-Kim, Jeremy Chang, I. Peter Shintaku, Peter D. Boasberg, Emma J. Taylor, Pamela N. Munster, Alain P. Algazi, Bartosz Chmielowski, Reinhard Dummer, Tristan R. Grogan, David Elashoff, Jimmy Hwang, Simone M. Goldinger, Edward B. Garon, Robert H. Pierce, Adil Daud |
| Abstract |
We explored the association between liver metastases, tumor CD8+ T cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the Phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non-small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival (PFS); [objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared to patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (odds ratio 1.852, P < 0.0001). In a subset of biopsied patients (n = 62), liver metastasis was associated with reduced CD8+ T cell density at the invasive tumor margin (liver metastasis+ group, n = 547164.8; liver metastasis -group, n = 1441250.7 P < 0.016). A reduced response rate and shortened PFS was also observed in NSCLC patients with liver metastasis (median PFS, 1.8 months, 95% CI 1.4-2.0), compared to those without liver metastasis (n = 119, median PFS, 4.0 months, 95% CI 2.1-5.1), P = 0.0094. Thus, liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases were associated with reduced marginal CD8+ T cell infiltration, providing a potential mechanism for this outcome. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 56% |
| United Arab Emirates | 1 | 6% |
| France | 1 | 6% |
| Italy | 1 | 6% |
| Unknown | 5 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 67% |
| Scientists | 3 | 17% |
| Practitioners (doctors, other healthcare professionals) | 2 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 193 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 42 | 22% |
| Student > Ph. D. Student | 24 | 12% |
| Other | 20 | 10% |
| Student > Doctoral Student | 15 | 8% |
| Student > Bachelor | 11 | 6% |
| Other | 23 | 12% |
| Unknown | 58 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 62 | 32% |
| Biochemistry, Genetics and Molecular Biology | 24 | 12% |
| Immunology and Microbiology | 11 | 6% |
| Agricultural and Biological Sciences | 11 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
| Other | 10 | 5% |
| Unknown | 69 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2021.
All research outputs
#1,856,819
of 22,963,381 outputs
Outputs from Cancer Immunology Research
#178
of 1,413 outputs
Outputs of similar age
#37,699
of 310,713 outputs
Outputs of similar age from Cancer Immunology Research
#3
of 27 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,413 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,713 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.